| Literature DB >> 3785891 |
H D Perry, K R Kenyon, D W Lamberts, G N Foulks, J A Seedor, L M Golub.
Abstract
Recent evidence shows tetracyclines have anticollagenolytic activity that may be clinically effective in disease treatment. This led us to use systemic tetracycline (oral tetracycline hydrochloride 1 g daily divided into 4 doses) as adjunctive therapy in treating 18 patients with persistent corneal epithelial defects. Fourteen of 18 patients healed their defects; within 48 hours (9 patients) and within two weeks (the other 5 responding patients). Two patients showed no effect and two showed disease progression.Entities:
Mesh：
Substances：
Year: 1986 PMID： 3785891 DOI： 10.1016/s0161-6420(86)33570-x
Source DB: PubMed Journal: Ophthalmology ISSN： 0161-6420 Impact factor: 12.079